Patients with a small aortic annulus (a predominantly female population with a higher risk of prosthesis–patient mismatch) represent a particularly challenging subgroup within TAVI. Self-expanding valves with a supra-annular design have demonstrated better early hemodynamic parameters compared with intra-annular balloon-expandable valves, at the expense of a higher incidence of paravalvular leak and conduction disturbances. However, the long-term clinical impact of these differences had not been clearly established. The aim of this study was to compare five-year clinical and echocardiographic outcomes between balloon-expandable and self-expanding valves in patients with a small aortic annulus undergoing TAVI.

A retrospective analysis was conducted using the RESOLVE registry from Cedars-Sinai Medical Center (Los Angeles, United States), which included 1,392 patients treated between 2015 and 2020. Of these, 423 had a small aortic annulus defined by computed tomography (area <430 mm²). In this cohort, 345 patients received balloon-expandable valves and 78 received self-expanding valves. The median age was 82 years, 78% were women, and surgical risk was intermediate (median STS score 4.37%; IQR 2.87–6.70). Mean body surface area was 1.70 m², and left ventricular ejection fraction was preserved in both groups. The mean aortic annulus area was 381 mm². Contemporary commercial valves were used, predominantly sizes 23 and 26 mm in the balloon-expandable group, and 23, 26, and 29 mm in the self-expanding group.
The primary endpoint was a composite of all-cause mortality, stroke, or hospitalization for heart failure at five years. Secondary endpoints included myocardial infarction, permanent pacemaker implantation, valve reintervention, and structural valve deterioration, defined according to VARC-3 criteria.
Five-year outcomes of TAVI in small aortic annulus: superior hemodynamic performance with self-expanding valves
From a hemodynamic standpoint, self-expanding valves showed a sustained superior performance over time, with significantly lower mean gradients and a larger indexed effective orifice area. At 30 days, the mean gradient was 6 ± 2 mmHg in the self-expanding group compared with 12 ± 3 mmHg in the balloon-expandable group (p<0.001), a difference that persisted at five years (6 ± 3 mmHg vs 13 ± 4 mmHg; p<0.001). The indexed effective orifice area was also greater with self-expanding valves (0.9 ± 0.2 cm²/m² vs 0.7 ± 0.2 cm²/m²; p=0.025). However, self-expanding valves were associated with a higher rate of moderate-to-severe paravalvular leak (7.7% vs 1.5%; p<0.001) and a greater need for post-dilatation (25.6% vs 2.3%; p<0.001).
Regarding clinical outcomes, at five years the primary endpoint occurred in 39.7% of patients with balloon-expandable valves and in 41.1% of those with self-expanding valves, with no statistically significant differences (adjusted HR 1.65; 95% CI 0.88–3.09; p=0.11). All-cause mortality was comparable between both groups (24.9% vs 28.2%; p=0.09), as were the rates of stroke, myocardial infarction, rehospitalization for heart failure, valve reintervention, and structural valve deterioration, which remained low and similar (19.7% vs 15.4%; p=0.64).
The most clinically relevant difference was observed in conduction disturbances: permanent pacemaker implantation was significantly more frequent in the self-expanding valve group (17.9% vs 6.1%), with an adjusted risk more than four times higher (HR 4.03; 95% CI 1.90–8.54; p<0.001). Additionally, a higher incidence of early stroke at 30 days was recorded in the self-expanding group (5.1% vs 0.6%; p=0.002).
Conclusion: The hemodynamic advantage of self-expanding valves does not translate into better clinical outcomes
In conclusion, in patients with a small aortic annulus undergoing TAVI, self-expanding valves provide a sustained hemodynamic advantage at five years, with lower gradients and a larger effective valve area. However, this benefit does not translate into a reduction in major clinical events or improved survival and is offset by a higher incidence of paravalvular leak and, particularly, permanent pacemaker implantation. These findings support an individualized selection of prosthesis type, balancing hemodynamic performance and clinical risk in each patient.
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology





